Abstracts tagged "pain"

Abstract Number: 1804 • ACR Convergence 2025
Pharmacology of LEVI-04, a novel treatment for OA
Simon Westbrook¹ and Kerry af Forselles², ¹Levicept Ltd, Sandwich, United Kingdom, ²Levicept, Sandwich, United Kingdom
Background/Purpose: LEVI-04 is a novel fusion protein comprising the extracellular domain of p75 neurotrophin receptor (p75NTR) coupled to IgG1 Fc, being developed for the treatment…
Abstract Number: 1380 • ACR Convergence 2025
Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach
Beatrice Dei¹, Stefano Donati¹, Gaetano La Rocca², Giovanni Fulvio¹, Federico Fattorini¹, Antonello Sulis¹, Michele Moretti¹, Elena Elefante¹, Francesco Ferro³, Giulia Ricci⁴, Marta Mosca⁵ and Chiara Baldini⁵, ¹Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁴Neurology Unit, University of Pisa, Pisa, Toscana, Italy, ⁵University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Neuropathic pain (NeP) is increasingly recognized as a relevant symptom domain in primary Sjögren’s disease (SjD), contributing to the disease burden beyond glandular involvement.…
Abstract Number: 1234 • ACR Convergence 2025
Serum Antibodies Against Glial Fibrillary Acidic Protein in Fibromyalgia: A Proof-of-Concept Study
Felipe Massó¹, Laura Aline Martinez-Martinez², Luis M Amezcua-Guerra³, Francisco Mercado⁴, Angélica Almanza⁵ and Manuel Martínez-Lavín¹, ¹Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ²Rheumatology Department at National Institute of Cardiology Ignacio Chávez, Mexico City, Federal District, Mexico, ³Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico city, ⁴Instituto Nacional de Psiquiatría Ramón del la Fuente Muñiz, Mexico city, Mexico, ⁵Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico city, Mexico
Background/Purpose: Fibromyalgia (FM) is a stress-related disorder in which dorsal root ganglia (DRG) may play a pivotal pathogenetic role. DRG exhibit unique stress-induced, pro-algesic physio-anatomy,…
Abstract Number: 1027 • ACR Convergence 2025
GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry
Nick McCormick¹, Jingyi Zhang², Emily Holladay², Fenglong Xie³ and Jeffrey Curtis⁴, ¹Auburn University, Auburn, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) such as semaglutide (SEM; GLP-1) and tirzepatide (TIR; GIP/GLP-1), were initially approved for type 2 diabetes management but…
Abstract Number: 0442 • ACR Convergence 2025
Beyond the Joints: The Impact of Non-Articular Pain on Patient-Reported Function in a Longitudinal Real-World Early RA Cohort
Charis Meng¹, Marie-France Valois², Caci Julia³, Yvonne Lee⁴, Bindee Kuriya⁵, Gilles Boire⁶, Hugues Allard-Chamard⁷, Carol Hitchon⁸, Louis Bessette⁹, Glen Hazlewood¹⁰, Carter Thorne¹¹, Susan J. Bartlett¹², Janet Pope¹³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²McGill University, Pointe-Claire, QC, Canada, ³Hospital for Special Surgery, New York, ⁴Northwestern University, Chicago, IL, ⁵Mount Sinai Health, Toronto, Canada, ⁶Retired, Sherbrooke, QC, Canada, ⁷Université de Sherbrooke, Sherbrooke, Canada, ⁸University of Manitoba, Winnepeg, Canada, ⁹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²McGill University, Beaconsfield, QC, Canada, ¹³University of Western Ontario, London, ON, Canada
Background/Purpose: A third of patients with early (e)RA report pain outside the joint or non-articular pain (NAP) despite RA treatment(1). NAP, both regional and widespread,…
Abstract Number: 2120 • ACR Convergence 2025
Analyzing Gender and Racial Disparities in Paget’s Disease of Bone: A Large-Scale Observational Study
Kinga Grzybowski¹, Ahmer Khan² and Arthur Lau³, ¹Jefferson Einstein Montgomery Hospital, Maspeth, NY, ²Jefferson Einstein Philadelphia Hospital, Philadelphia, ³Jefferson Einstein Hospital, Maple Glen, PA
Background/Purpose: Osteitis deformans, commonly referred to as Paget’s Disease of the Bone (PDB), affects adults over the age of 55, mainly of European descent and…
Abstract Number: 1800 • ACR Convergence 2025
The Role of Nociceptor-Expressed Piezo2 in Nervous System Immune Cell Infiltration in a Mouse Model of Osteoarthritis
Natalie Adamczyk¹, Terese Geraghty², Shingo Ishihara³, alia obeidat², Jun Li², Anne-Marie Malfait² and Rachel Miller¹, ¹Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, Chicago, ³Rush University, Chicago
Background/Purpose: Osteoarthritis is one of the leading causes of chronic pain and disability worldwide with 500 million people affected. We have previously reported that nociceptor-conditional…
Abstract Number: 1298 • ACR Convergence 2025
Identifying Psychosocial Profiles in Youth with Chronic Musculoskeletal Pain: A K-Means Clustering Analysis of Resilience Subgroups
Sabrina Gmuca¹, Jan Leonard², Alexis Z. Tomlinson², Mackenzie McGill², Nellie Butler², Rui Xiao³, Peter F. Cronholm³, Tonya M. Palermo⁴, Jami F. Young⁵, Abby R. Rosenberg⁶ and Pamela Weiss⁷, ¹Children's Hospital of Philadelphia; University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Washington School of Medicine; Seattle Children’s Research Institute, Seattle, ⁵Children's Hospital of Philadelphia; University of Pennsylvania, Philadelphia, ⁶Dana-Farber Cancer Institute; Boston Children’s Hospital; Harvard Medical School, Boston, ⁷Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Psychological resilience is low among youth with chronic musculoskeletal pain (CMP) at baseline. We aimed to explore resilience profiles among youth with CMP during…
Abstract Number: 1235 • ACR Convergence 2025
Demystifying Pain in patients with Lupus: How much is it Lupus and How much is it Other Stuff?
Meenakshi Jolly, Rush University, Chicago
Background/Purpose: Pain in patients with Systemic Lupus Erythematosus (SLE) is not well understood. There is role of active disease in pain (e.g. arthritis, serositis) also…
Abstract Number: 1021 • ACR Convergence 2025
Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases
Kristin Wipfler¹ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cannabis use has increased substantially in the general population over the past decade, driven by changing legal landscapes and expanding public interest in its…
Abstract Number: 0440 • ACR Convergence 2025
The Painful Truth: Non-Articular Pain’s Impact on Rheumatoid Arthritis Assessment after Initiating a new DMARD for Active Disease
Charis Meng¹, Jing Song², Lutfiyya muhammad³, Caci Julia⁴, Tuhina Neogi⁵, Marcy Bolster⁶, Wendy Marder⁷, Clifton Bingham⁸ and Yvonne Lee⁹, ¹Hospital for Special Surgery, New York, NY, ²Northwestern University Feinberg School of Medicine, Worthington, MN, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Hospital for Special Surgery, New York, ⁵Boston University School of Medicine, Boston, MA, ⁶Massachusetts General Hospital, Concord, MA, ⁷University of Michigan, Ann Arbor, MI, ⁸Johns Hopkins University, Baltimore, MD, ⁹Northwestern University, Chicago, IL
Background/Purpose: RA-related pain is typically thought of as pain in the joints. However, non-articular pain (NAP) is also common, persisting in 1/3 of patients with…
Abstract Number: 2112 • ACR Convergence 2025
Which drugs are associated with the development of osteonecrosis of the jaw? clinical and epidemiological analysis of a cohort of patients diagnosed with osteonecrosis of the jaw.
Esther Monleon Acosta¹, Alicia Pérez González², José Andrés Rodríguez Fernández², Pedro José Manuel Hernández², María del Rosario Oliva Ruiz², José María Andreu Ubero², Paloma Valentina Castillo Dayer², Gloria Albaladejo Paredes³, Carlos Fernández Díaz⁴, Angela Egea Fuentes², Montserrat Fernández Salamanca² and Vicente Cogolludo Campillo⁵, ¹Hospital Santa Lucia, Cartagena, Spain, ²Hospital General Universitario Santa Lucia, Cartagena, Spain, ³Hospital General Universitario Santa Lucía, CARTAGENA, Spain, ⁴H.U. Santa Lucia, Murcia, Spain, ⁵Hospital General Universitario Santa Lucia, Santa Lucia, Cartage, Spain
Background/Purpose: Osteonecrosis of the jaw (ONJ) is defined as avascular necrosis of bone located in the maxillofacial region with the presence of exposed bone or…
Abstract Number: 1794 • ACR Convergence 2025
OA-associated pain sensitivity is reduced in OA-protected MRL/MpJ mice, partially mediated by the gut microbiome, and transferable via microbiome transplantation
Gabriella Dyson¹, Montana Barrett¹, Nicholas Hanebutt¹, Aleksander Szymczak², Cindy Miranda Brawner¹, Pratibha Dube³, Ausitn Lopez¹, Padmaja Mehta-d'Souza¹ and Matlock Jeffries², ¹Oklahoma Medical Research Foundation, Oklahoma City, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Edmond, OK
Background/Purpose: MRL/MpJ (MRL) mice are protected from developing post-traumatic osteoarthritis (OA) histologic changes. We have previously shown the gut microbiome to play a key role…
Abstract Number: 1289 • ACR Convergence 2025
Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus
Jida Jaffan¹, Tala El Tal², Lawrence Ng³, Asha Jeyanathan⁴, Hunter Hogarth⁵, Adrienne Davis⁴, Linda Hiraki⁵, Deborah Levy⁵, Zahi Touma⁶, Natoshia Cunningham⁷, Ashley Danguecan⁸ and Andrea Knight⁸, ¹The Hospital for Sick Children/ University of Toronto, Toronto, ON, Canada, ²Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Michigan State University, Grand Rapids, MI, ⁸Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Pain is a common symptom in childhood-onset systemic lupus erythematosus (cSLE) which impacts health-related quality of life. Its relationship to disease measures over time…
Abstract Number: 1233 • ACR Convergence 2025
Synovial Joint Transcriptomic Differences in Individuals with Knee Osteoarthritis and Neuropathic Pain Symptomology
Joseph Lesnak¹, Michael Zuscik², Michael Dayton², Craig Hogan², Prabil Kaini², Andrew Clauw³, Jennifer Seifert⁴, Michael Clay⁵, Theodore Price¹ and Larry Moreland⁶, ¹University of Texas at Dallas, Dallas, ²University of Colorado School of Medicine, Aurora, ³Univ of Colorado, Aurora, CO, ⁴University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁵University of Colorado, Aurora, CO, ⁶University of Colorado, Denver, CO
Background/Purpose: Osteoarthritis (OA) is a painful disease of the synovial joint and is the most common form of arthritis with a large global burden. A…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].